Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs
Executive Summary
Every month, F-D-C Reports' Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA's own review documents, including the discipline reviews, decision memos, meeting minutes, e-mails, and other documents, the publication strives to illuminate the agency decision-making process.
You may also be interested in...
With Avastin Approval For Breast Cancer, Will More Patients Hit Price Cap?
FDA approval of Genentech's Avastin for first-line treatment of metastatic breast cancer may trigger the first significant trial of the biotech's Avastin patient assistance program, which caps annual drug expenditures at $55,000 for approved indications but has not seen much utilization by colorectal or non-small cell lung cancer patients
GSK Tykerb Priced At Discount To Herceptin In Metastatic Breast Cancer
GlaxoSmithKline is pricing its breast cancer therapy Tykerb at a slight discount to Genentech's Herceptin (trastuzumab) in the metastatic breast cancer setting
Shire Turns Attention To Vyvanse Two Years Before Adderall XL Generics
Shire will seek to transition patients from Adderall XR to its next-generation attention deficit/hyperactivity disorder drug Vyvanse prior to 2009, when Adderall XR generics are expected to launch